aldosterone has been researched along with Depressive Disorder, Major in 9 studies
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone treatment induced an anhedonic state manifested by decreased sucrose preference." | 5.38 | Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. ( Babic, S; Flynn, ME; Hlavacova, N; Jezova, D; Murck, H; Ondrejcakova, M; Poundstone, PK; Wes, PD, 2012) |
| "Aldosterone treatment induced an anhedonic state manifested by decreased sucrose preference." | 1.38 | Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. ( Babic, S; Flynn, ME; Hlavacova, N; Jezova, D; Murck, H; Ondrejcakova, M; Poundstone, PK; Wes, PD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Murck, H | 4 |
| Lehr, L | 1 |
| Jezova, D | 5 |
| Izakova, L | 2 |
| Hlavacova, N | 3 |
| Segeda, V | 2 |
| Kapsdorfer, D | 1 |
| Morovicsova, E | 1 |
| Bednarova, A | 1 |
| Braunisch, MC | 1 |
| Konrad, C | 2 |
| Kircher, T | 2 |
| Heinzmann, JM | 1 |
| Kloiber, S | 1 |
| Ebling-Mattos, G | 1 |
| Bielohuby, M | 1 |
| Schmidt, MV | 1 |
| Palme, R | 1 |
| Holsboer, F | 1 |
| Uhr, M | 1 |
| Ising, M | 1 |
| Touma, C | 1 |
| Büttner, M | 1 |
| Hallberg, L | 1 |
| Westrin, A | 1 |
| Isaksson, A | 1 |
| Janelidze, S | 1 |
| Träskman-Bendz, L | 1 |
| Brundin, L | 1 |
| Wes, PD | 1 |
| Ondrejcakova, M | 1 |
| Flynn, ME | 1 |
| Poundstone, PK | 1 |
| Babic, S | 1 |
| Fischer, A | 1 |
| Otte, C | 1 |
| Krieger, T | 1 |
| Nicholls, RA | 1 |
| Krüger, S | 1 |
| Ziegler, KJ | 1 |
| Schulz, KH | 1 |
| Heesen, C | 1 |
| Gold, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Randomized Placebo Controlled Study on the Effect of Enoxolone ( 11-beta Hydroxysteroid-dehydrogenase Type 2 Inhibitor) on the RAAS, Autonomic and Imaging Biomarkers and the Outcome of Depression[NCT05570110] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aldosterone and Depressive Disorder, Major
| Article | Year |
|---|---|
A viewpoint on aldosterone and BMI related brain morphology in relation to treatment outcome in patients with major depression.
Topics: Aldosterone; Body Mass Index; Brain; Depression; Depressive Disorder, Major; Humans; Hydrocortisone; | 2023 |
Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression.
Topics: Aldosterone; Animals; Brain; Corticosterone; Depressive Disorder, Major; Female; Glucocorticoids; Hu | 2014 |
7 other studies available for aldosterone and Depressive Disorder, Major
| Article | Year |
|---|---|
Salivary Aldosterone, Cortisol, and Their Morning to Evening Slopes in Patients with Depressive Disorder and Healthy Subjects: Acute Episode and Follow-Up 6 Months after Reaching Remission.
Topics: Acute Disease; Adult; Aldosterone; Anxiety; Bipolar Disorder; Circadian Rhythm; Depression; Depressi | 2020 |
Aldosterone concentrations in saliva reflect the duration and severity of depressive episode in a sex dependent manner.
Topics: Adult; Aged; Aldosterone; Analysis of Variance; Circadian Rhythm; Depressive Disorder, Major; Female | 2017 |
Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
Topics: Adult; Aldosterone; Antidepressive Agents; Antipsychotic Agents; Biomarkers; Blood Pressure; Depress | 2019 |
Mice selected for extremes in stress reactivity reveal key endophenotypes of major depression: a translational approach.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Animals; Brain; Corticosterone; Corticotro | 2014 |
Decreased aldosterone in the plasma of suicide attempters with major depressive disorder.
Topics: Aldosterone; Analysis of Variance; Depressive Disorder, Major; Female; Humans; Male; Psychiatric Sta | 2011 |
Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder.
Topics: Aldosterone; Animals; Depression; Depressive Disorder, Major; Gene Expression Regulation; Hyperaldos | 2012 |
Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression.
Topics: Adult; Aldosterone; Anti-Inflammatory Agents; Cell Proliferation; Cells, Cultured; Depressive Disord | 2012 |